Arthritis and Myositis in a Patient Treated with Programmed Cell Death-1 (PD-1) Inhibitor Pembrolizumab for Lung Cancer

Immune checkpoint inhibitors (ICIs) are a new class of drug that have demonstrated efficacy across many cancer types. Because of their nature and mode of action, ICIs unleash immune activation raising concerns as to whether they can be used in patients with concomitant autoimmune or auto-inflammator...

Descripción completa

Detalles Bibliográficos
Autores principales: Pagkopoulou, Eleni, Simopoulou, Theodora, Maragkouli, Eleni, Perifanou-Sotiri, Stamatia, Kotsakis, Athanasios, Bogdanos, Dimitrios P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Mediterranean Journal of Rheumatology (MJR) 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7641028/
https://www.ncbi.nlm.nih.gov/pubmed/33163870
http://dx.doi.org/10.31138/mjr.31.3.355

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7641028/
https://www.ncbi.nlm.nih.gov/pubmed/33163870
http://dx.doi.org/10.31138/mjr.31.3.355

Ejemplares similares